MEXAZOLAM

Details

Stereochemistry	MIXED
Molecular Formula	C18H16Cl2N2O2
Molecular Weight	363.238
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1COC2(N1CC(=O)NC3=C2C=C(Cl)C=C3)C4=CC=CC=C4Cl

InChI

InChIKey=ANUCDXCTICZJRH-UHFFFAOYSA-N

InChI=1S/C18H16Cl2N2O2/c1-11-10-24-18(13-4-2-3-5-15(13)20)14-8-12(19)6-7-16(14)21-17(23)9-22(11)18/h2-8,11H,9-10H2,1H3,(H,21,23)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26000220
Curator's Comment: description was created based on several sources, including http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1538

Mexazolam (trade names Melex and Sedoxil) is indicated for the management of anxiety with or without psychoneurotic conditions. In adult patients, the recommended daily dosage of mexazolam is 1-3 mg, administered three times daily. Mexazolam is metabolised via the CYP3A4 pathway.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Anxiety 275 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1538	Curative		Phase III 665	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
1 mg 3 times / day multiple, oral Dose: 1 mg, 3 times / day Route: oral Route: multiple Dose: 1 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26000220/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/26000220/	Other AEs: Drowsiness... Other AEs: Drowsiness (8 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/26000220/

AEs

AE	Significance	Dose	Population
Drowsiness	8 patients	1 mg 3 times / day multiple, oral Dose: 1 mg, 3 times / day Route: oral Route: multiple Dose: 1 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26000220/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/26000220/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 substrate 1946	inhibitor 2438 substrate 1193	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP1A2 2153	CYP2C 16 CYP1A 26 CYP2C11 9 CYP2B6 776 CYP3A5 446 CYP1A2 1197 CYP2A6 626 CYP2C8 810 CYP2E1 729

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671199#sid=170465840	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671201#sid=170465840	yes [IC50 1.3803 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645840#sid=170465840	yes [IC50 10.964 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=170465840	yes [IC50 24.5454 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671197#sid=170465840	yes [IC50 4.3649 uM]

Drug as victim

Target	Modality	Activity
CYP1A 26	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11181496/	no
CYP1A2 1197	substrate 4014 Sources: https://www.koreascience.or.kr/article/CFKO199411922095318.page	no
CYP2A6 626	substrate 4014 Sources: https://www.koreascience.or.kr/article/CFKO199411922095318.page	no
CYP2C 16	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11181496/	no
CYP2C8 810	substrate 4014 Sources: https://www.koreascience.or.kr/article/CFKO199411922095318.page	no
CYP2C9 1193	substrate 4014 Sources: https://www.koreascience.or.kr/article/CFKO199411922095318.page	no
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11181496/	no
CYP2E1 729	substrate 4014 Sources: https://www.koreascience.or.kr/article/CFKO199411922095318.page	no
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11181496/ \| https://www.koreascience.or.kr/article/CFKO199411922095318.page	yes [Km 29.2 uM]
CYP2B6 776	substrate 4014 Sources: https://www.koreascience.or.kr/article/CFKO199411922095318.page	yes
CYP2C11 9	substrate 4014 Sources: https://link.springer.com/referenceworkentry/10.1007/978-3-319-56015-1_162-1	yes
CYP3A5 446	substrate 4014 Sources: https://www.koreascience.or.kr/article/CFKO199411922095318.page	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671200#sid=170465840

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
Generalized skin drug eruption to natalizumab in a patient with multiple sclerosis.	2010-06-15	20579469
Passiflora for anxiety disorder.	2007-01-24	17253512
Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?	2005	15743490
The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam.	2003-09	12911366
Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder.	2003	17535036
Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes.	2002-08	12124308
A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro.	2001-03	11181496

Patents

Sample Use Guides

In Vivo Use Guide

1-3 mg, administered three times daily

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

MEXAZOLAM

Official Name

English

MELEX

Preferred Name

English

MEXAZOLAM [MART.]

Common Name

English

10-CHLORO-11B-(O-CHLOROPHENYL)-2,3,7,11B-TETRAHYDRO-3-METHYLOXAZOLO(3,2-D)(1,4)BENZODIAZEPIN-6(5H)-ONE

Common Name

English

mexazolam [INN]

Common Name

English

MEXAZOLAM [MI]

Common Name

English

Mexazolam [WHO-DD]

Common Name

English

10-CHLORO-11B-(2-CHLOROPHENYL)-2,3,7,11B-TETRAHYDRO-3-METHYLOXAZOLO(3,2-D)(1,4)BENZODIAZEPIN-6(5H)-ONE

Common Name

English

MEXAZOLAM [JAN]

Common Name

English

CS-386

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C1012